This study is an open-label extension to protocol B5161002 and will provide an assessment of the long term safety, efficacy, pharmacodynamics and pharmacokinetics of intravenous dosing of PF 06252616 in boys with Duchenne muscular dystrophy. Approximately 105 eligible subjects will be assigned to receive a monthly individualized maximum tolerated dose based on their tolerability profile/data from B5161002. This study will not contain a placebo comparator. Subjects will undergo safety evaluations (Laboratory, cardiac monitoring, physical exams, x-ray, MRI), functional capacity evaluations (4 stair climb, range of motion, strength testing, Northstar Ambulatory Assessment, upper limb functional testing, six minute walk test and pulmonary function tests) and pharmacokinetic testing.

Start Date13 Oct 2016

Sponsor / Collaborator

Pfizer Inc.

NCT02841267

/ CompletedPhase 1/2IIT

A Phase 1b/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Ambulatory Participants With LGMD2I

The investigational product PF 06252616, a humanized anti myostatin monoclonal antibody that neutralizes myostatin (GDF8) is in development for the treatment of Limb Girdle Muscular Dystrophy 2I (LGMD2I) to preserve and/or improve muscle function.
This study will provide the clinical assessment of the safety, tolerability, Pharmacokinetics and Pharmacodynamics of PF 06252616 following repeat IV doses in ambulatory adults with LGMD2I.

Start Date01 Jul 2016

Sponsor / Collaborator

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

[+1]

NCT02310763

/ TerminatedPhase 2

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06252616 IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY

This is a Phase 2 randomized, 2-period, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, efficacy, PK and PD of PF-06252616 administered to ambulatory boys diagnosed with Duchenne Muscular Dystrophy. Three intravenous (IV) dose levels will be investigated in a within subject dose escalating fashion. Subjects will be randomly assigned to 1 of 3 sequence groups for approximately 96 weeks (2 periods of 48 weeks each). In period 1, two of the sequence groups will receive PF-06252616 and one sequence group will receive placebo. In period 2, the placebo group will switch to PF-06252616 and the two remaining sequence groups will either receive placebo or PF-06252616. Efficacy will be based on an observed mean change from baseline on function (4 stair climb) of PF-06252616 as compared to the placebo at the end of period 1. Period 2 provides an opportunity to evaluate PK. Subjects will receive monthly IV infused doses of either PF-06252616 or placebo and will undergo safety evaluations (Laboratory, cardiac monitoring, physical exams, x-ray, MRI), functional evaluations (pulmonary function testing, 4 stair climb, range of motion, strength testing, Northstar Ambulatory Assessment, upper limb functional testing and the six minute walk test), pharmacokinetic testing and pharmacodynamic testing to evaluate changes in muscle volume (MRI).

Start Date24 Nov 2014

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Domagrozumab

100 Translational Medicine associated with Domagrozumab

100 Patents (Medical) associated with Domagrozumab

Literatures (Medical) associated with Domagrozumab

01 Mar 2025·MUSCLE & NERVE

Relationship Between Quantitative Magnetic Resonance Imaging Measures and Functional Changes in Patients With Duchenne Muscular Dystrophy

Article

Author: Palmer, Jeffrey ; Karlsson, Markus ; Widholm, Per ; Ahlgren, André ; McCrady, Allison ; Sherlock, Sarah P. ; Dahlqvist Leinhard, Olof ; Aghamolaey, Haleh

ABSTRACT:

Introduction/Aims:

Improved methodologies to monitor the progression of Duchenne muscular dystrophy (DMD) are needed, especially in the context of clinical trials. We report changes in muscle magnetic resonance imaging (MRI) parameters in participants with DMD, including changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI) and their relationship to changes in functional parameters.

Methods:

MRI data were obtained as part of a clinical study (NCT02310763) of domagrozumab, an antibody‐targeting myostatin that negatively regulates skeletal muscle mass. This post hoc analysis evaluated participants with Dixon MRI data and corresponding functional data at baseline and weeks 49 and 97. Images were analyzed to evaluate changes in adductors, hamstrings, and quadriceps.

Results:

There was a positive correlation between increases in LMV and function. LMV changes in adductors (R = 0.51) and quadriceps (R = 0.54) showed a stronger correlation with function than LMV changes in hamstrings (R = 0.30). There was a negative correlation between MFF and MFI, respectively, and function in adductors (R = −0.57, R = −0.42), quadriceps (R = −0.59, R = −0.50), and hamstrings (R = −0.53, R = −048). Participants with preserved North Star Ambulatory Assessment scores had high total LMV (LMVtot) and low total MFI (MFItot). Low ratios of LMVtot to MFItot, or participants with small LMVtot and high MFItot, appeared to have a rapid decline in function and loss of ambulation.

Discussion:

These findings support the use of MRI biomarkers as potential surrogate endpoints in clinical trials of patients with DMD.Trial Registration:ClinicalTrials.gov identifiers: NCT02310763

01 Jan 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Simultaneous detection of myostatin-targeting monoclonal antibodies in dried blood spots and plasma using liquid chromatography-tandem mass spectrometry with field asymmetric ion mobility spectrometry

Article

Author: Seo, Yoondam ; Hwang, Jiin ; Min, Hophil ; Lee, Hwa Jeong ; Lee, Hyeon-Jeong ; Lee, Gahyeon

Transforming growth factor-β superfamily members, such as myostatin, growth/differentiation factor 11, and activin A, negatively regulate skeletal muscle mass. Inhibitors targeting these cytokines or activin receptor type IIB have the potential to treat muscular diseases and enhance physical performance. However, because of their effects on muscle mass and potential misuse, they are strictly prohibited in sports. Given the high potential for misuse as a doping agent in sports, effective analytical methods for these prohibited antibodies targeting these specific cytokines or their receptor are critically needed. In this study, we aimed to develop and validate a multitarget method to detect the prohibited transforming growth factor-β superfamily-targeting monoclonal antibodies, such as landogrozumab, domagrozumab, and the activin receptor type IIB-targeting antibody, bimagrumab, in human plasma and dried blood spot (DBS) samples using liquid chromatography-tandem mass spectrometry. Antibodies were purified from both the DBS and plasma samples using protein G magnetic beads and field-asymmetric ion mobility spectrometry (FAIMS) to minimize interference, followed by liquid chromatography-tandem mass spectrometry analysis. The validation process included tests for specificity, selectivity, linearity, limit of detection (LOD), limit of identification, precision, recovery, carryover effect, and matrix effect. The LODs for the target antibodies were identical in both DBS and plasma samples at 0.1 µg/mL for landogrozumab heavy and light chains, as well as 0.25 µg/mL for the domagrozumab light chain and 0.25 µg/mL for the bimagrumab heavy chain. However, the heavy chain of domagrozumab exhibited an LOD of 0.5 µg/mL in DBS and 1 µg/mL in plasma. The analytical method demonstrated strong linearity, with R² values greater than 0.99 for both plasma and DBS, and no carryover effect. Precision (CV%) was below 15 % at both middle (1 or 5 µg/mL; specific to the heavy chain of domagrozumab in plasma) and high (10 µg/mL) concentrations and was less than 20 % at the LOD. The selectivity and specificity indicated no interference in the analysis of target mAbs in different blood samples. Recovery was 31.6-49.8 % for DBS and 51.4-85.3 % for plasma, with no significant matrix effect. This study provides an effective method for doping analysis and novel protein detection.

01 Dec 2022·Clinical pharmacology and therapeutics

Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy

Article

Author: Tan, Beesan ; Harnisch, Lutz O. ; Nicholas, Timothy ; Purohit, Vivek S. ; Wojciechowski, Jessica ; Dua, Pinky

Myostatin, a negative regulator of skeletal muscle growth, is a therapeutic target in muscle‐wasting diseases. Domagrozumab, a humanized recombinant monoclonal antibody, binds myostatin and inhibits activity. Domagrozumab was investigated in a phase II trial (NCT02310763) as a potential treatment for boys with Duchenne muscular dystrophy (DMD). Pharmacokinetic/pharmacodynamic (PK/PD) modeling is vital in clinical trial design, particularly for determining dosing regimens in pediatric populations. This analysis sought to establish the PK/PD relationship between free domagrozumab and total myostatin concentrations in pediatric patients with DMD using a prior semimechanistic model developed from a phase I study in healthy adult volunteers (NCT01616277) and following inclusion of phase II data. The refined model was developed using a multiple‐step approach comprising structural, random effects, and covariate model development; assessment of model adequacy (goodness‐of‐fit); and predictive performance. Differences in PKs/PDs between healthy adult volunteers and pediatric patients with DMD were quantitatively accounted for and evaluated by predicting myostatin coverage (the percentage of myostatin bound by domagrozumab). The final model parameter estimates and semimechanistic target‐mediated drug disposition structure sufficiently described both domagrozumab and myostatin concentrations in pediatric patients with DMD, and most population parameters were comparable with the prior model (in healthy adult volunteers). Predicted myostatin coverage for phase II patients with DMD was consistently > 90%. Baseline serum myostatin was ~ 65% lower than in healthy adult volunteers. This study provides insights into the regulation of myostatin in healthy adults and pediatric patients with DMD. Clinicaltrials.gov identifiers: NCT01616277 and NCT02310763.

News (Medical) associated with Domagrozumab

24 Oct 2018

·www.biospace.com

Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week

Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018. Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018. Monday, October 29 BrainStorm Cell Therapeutics – Brainstorm, located in New York City and Petach Tikvah, Israel, focuses on developing adult stem cell therapies derived from autologous bone marrow cells to treat neurodegenerative diseases. In the third quarter, the company completed a pre-specified interim analysis of safety outcomes for the first 31 participants in the Phase III trial for NurOwn in amyotrophic lateral sclerosis (ALS). No safety concerns were identified. In September, Arturo O. Araya came on board as chief commercial officer. Araya was formerly Global Head of Commercial of Novartis ’ Cell and Gene Therapies Unit. Tuesday, October 30 Allergan – In August, Allergan exercised its option to develop and commercialize Cambridge, Mass.-based Editas Medicine ’ s EDIT-101 for the treatment of LCA10. Allergan paid Editas $15 million in conjunction with the exercise, and Editas is eligible for another $25 million once EDIT-101 is accepted by the Food and Drug Administration (FDA) for an investigational new drug (IND) application. Later in the month, the FDA rejected Allergan’s new drug application (NDA) for ulipristal acetate (UPA) for the treatment of abnormal uterine bleeding in women with uterine fibroids. In early September, Allergan launched the new SkinMedica LUMIVIVE System. And later in September, the company announced plans to build the first Medical Aesthetics Innovation Center in Chengdu, China. Pfizer – In late August, Pfizer released positive primary results from its Phase III trial of Tafamidis in Transthyretin Cardiomyopathy (ATTR-ACT), but only days later terminated two ongoing clinical trials of domagrozumab for Duchenne muscular dystrophy (DMD), both Phase II trials. In late September, the FDA granted Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Breakthrough Therapy designation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes. And on September 27, the FDA approved the company’s Vizimpro (dacomitinib) for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved assay. Clovis Oncology – In early August, Clovis announced the randomization of the first patient in its Phase III ATHENA trial to evaluate the combination of Rubraca (rucaparib) and Bristol-Myers Squibb ’s Opdivo (nivolumab) for advanced ovarian cancer. In October the FDA granted Breakthrough Therapy designation for Rubraca as a monotherapy for adults with BRCA1/2-mutated mCRPC who have had at least one previous androgen receptor-directed therapy and taxane-based chemotherapy. And on October 19, the company presented initial results from its ongoing TRITON program for Rubraca in metastatic castration-resistant prostate cancer. Wednesday, October 31 Acorda Therapeutics – At the beginning of this quarter, Acorda announced that Rick Batycky, its chief technology officer, was leaving the company as of August 20. David Lawrence, the company’s chief of business operations, was taking over the company’s Chelsea, Mass. manufacturing plant, which produces Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine). Burkhard Blank, the company’s chief medical officer, was taking over the company’s Pharmaceutical Development and Technical Operations teams. And on September 10, the United States Court of Appeals for the Federal Circuit, upheld the U.S. District Court for the District of Delaware’s decision to invalidate four Ampyra patents. Takeda Pharmaceutical – This will be the second-quarter report on Takeda’s fiscal year, having reported Q1 results on July 31. Since then, the company has announced a broad range of partnerships and deals, including opening a production site for Ninlaro (ixazomib) in Yaroslavl, Russia; creating a joint investment fund with Japan-based Alternative Asset Management Firm, Whiz Partners with a goal of promoting a drug discovery ecosystem in Japan; and signing a liver disease partnership with Ambys Medicines, in Redwood City, Calif. The next quarterly report will undoubtedly include some update on the company’s acquisition of Shire. On September 14, the deal was approved by the State Administration for Market Regulation in China. It received approval in the U.S. in mid-July, and in late August in Brazil. Thursday, November 1 Agios Pharmaceuticals – It’s been a relatively quiet quarter for Agios, although a busy year. Updates for the quarter will likely include progress on Tibsovo (ivosidenib), which was approved by the FDA for adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation in late July. The company’s first drug, Idhifa (enasidenib), with Celgene , was approved in August 2017, so this quarter will mark a full year of sales. Also, in September, the company announced that David Schenkein, the company’s executive chairman of the board and chief executive officer, will step down and be replaced by Jacqualyn Fouse as CEO. Shire – Although the pending acquisition by Takeda is likely to be high on the list of topics covered, Shire has had quite a bit of activity in the quarter. On August 23, the FDA approved Takhzyro (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older. On September 12, the European Commission (EC) granted Marketing Authorization for Veyvondi for bleeding events and treatment and prevention of surgical bleeding in adults with von Willebrand disease (VWD) when desmopressin treatment is ineffective. Teva Pharmaceuticals – The Israeli company announced that the FDA approved Ajovy (fremanezumab-vfrm) for migraine on September 14. Later in the month the company filed for a generic version of Cialis (tadalafil) in the U.S. And on October 21, the company, with State of New Jersey Governor Phil Murphy, formalized the company’s consolidation of its North America Commercial business areas into New Jersey. They will be in Parsippany-Troy Hills. Friday, November 2 AbbVie – On August 22, AbbVie released data from its Phase III ELARIS UF-EXTEND trial that showed its low-dose hormone therapy, Elagolix, reduced heavy menstrual bleeding in women with uterine fibroids. Five days later, the FDA approved Imbruvica plus Rituxan (rituximab) for patients with Waldenstrom’s macroglobulinemia (WM). And in mid-September, the company released new patient-reported outcomes data from three Phase III trials evaluating risankizumab in adults with moderate to severe plaque psoriasis.

Phase 3Drug ApprovalBreakthrough TherapyClinical ResultPhase 2

30 Aug 2018

·www.biospace.com

Pfizer Terminates Two DMD Studies Following Data Review

Diagnosis of Muscular Dystrophy closeup. Medical book guide for doctor neurologist with heading text of neurological disease Muscular Dystrophy surrounded neurological hammer and stethoscope Shidlovski/Getty Images/iStockphoto Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD). Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD). The company announced this morning that it will terminate a Phase II safety and efficacy study and an open-label extension study. Pfizer said the Phase II study did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4 Stair Climb (in seconds) following one year of treatment with domagrozumab, as compared to placebo. Pfizer said that further evaluation of secondary evidence did not support a significant treatment effect. The company said that a decision to terminate the trial was made following a “thorough review of data available at the time of the primary analysis.” The open-label extension study was designed to evaluate the long-term safety and efficacy of domagrozumab. Pfizer also noted that the studies were not terminated due to safety reasons. “We are disappointed by these results and while we are not progressing with the studies, the data will contribute to a greater understanding of this disease and we will evaluate the total data set to see if there is a place for this medicine in muscular diseases,” Seng Cheng, chief scientific officer of Pfizer’s Rare Disease Research Unit said in a statement. “We are extremely grateful to all those involved with this trial, especially the boys who participated, and their families.” While Pfizer halted those studies, the company noted that it is continuing its research into developing DMD treatments. Pfizer currently has one ongoing clinical trial in DMD with a gene therapy, PF-06939926, an investigational, recombinant AAV9 capsid carrying a truncated or shortened version of the human dystrophin gene (mini-dystrophin) under the control of a human muscle-specific promoter. The AAV-based gene therapy program came from Pfizer’s acquisition of Chapel Hill, N.C.-based Bamboo Therapeutics . In addition to the DMD therapy, that acquisition provided Pfizer with pre-clinical assets for Friedreich’s Ataxia and Canavan disease, and a Phase I asset for Giant Axonal Neuropathy. Currently, there is only one approved DMD treatment in the United States, Sarepta Therapeutics ’ Exondys 51, which skips the exon 51 mutation in DMD patients. DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs spreads to the arms, neck and other areas. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 boys born worldwide. The condition is universally fatal, and death usually occurs before the age of 30.

Phase 2AcquisitionPhase 1

01 May 2018

·www.biospace.com

Pfizer’s First Quarter Marked by Strong Pipeline, Jump in Profit, but Lower Revenue than Expected

Overall, Pfizer posted a good first quarter, with sales slightly higher and a 14 percent increase in profits due to lower restructuring costs and a significantly lower tax rate. However, revenue was below Wall Street expectations. Overall, Pfizer posted a good first quarter, with sales slightly higher and a 14 percent increase in profits due to lower restructuring costs and a significantly lower tax rate. However, revenue was below Wall Street expectations. Overall revenues for the quarter were up only one percent, reporting a total of $12.9 billion, up from $12.779 billion in the first quarter of 2017. The company’s Innovative Health division reported $7.820 billion, up six percent from the first quarter in 2017, and Essential Health reported $5.077 billion, down five percent from the previous year’s first quarter. “Our first-quarter 2018 financial results were solid, driven by continued strength from our anchor brands, primarily Ibrance, Eliquis and Xeljanz,” Ian Read, Pfizer’s chairman and chief executive officer, said in a statement. “The Essential Health business delivered strong growth in emerging markets and biosimilars but was negatively impacted by continued legacy Hospira product supply shortages in the U.S. as well as product losses of exclusivity. We remain focused on executing our commercial strategies, managing expenses, advancing our pipeline and prudently allocating our capital to position Pfizer for sustainable success.” There’s still no real news on Pfizer’s Consumer Healthcare business. Around October 2017, the company decided to sell or spin off that division. The brand has at least five major categories: dietary supplements, pain management, gastrointestinal, respiratory and personal care. Brand name products include Centrum, Caltrate, Emergen-C, Thermacare, Nexium 24 Hour, Robitussin, ChapStick and Anbesol. Ten of the company’s brands each exceeded $100 million in sales in 2016. It is valued between $15 and $20 billion. In March, it looked like either Reckitt Benckiser Group or GlaxoSmithKline would buy the unit, but both walked away from the deal. Pfizer today indicated it expects to make a decision about the unit this year. The consumer unit, which is part of the company’s innovative unit, gained seven percent. The company benefited from the Trump tax deal. It used part of the extra money available to pay shareholders $2 billion in dividends and to buy back $6.1 billion of its own shares. The company’s effective tax rate on adjusted income is about 17 percent. Pfizer also provided a comprehensive pipeline update. The company currently had 13 programs in Phase III, including Bavencio (avelumab) for non-small cell lung cancer, gastric cancer, ovarian cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, and in collaboration with Merck KGaA , urothelial cancer. It also has six biosimilars programs in registration/Phase III, including possible copycats for Humira (adalimumab), Avastin (bevacizumab), Epogen and Procrit (epoetin alfa), Neupogen (filgrastim), Rituxan/MabThera (rituximab) and Herceptin (trastuzumab). Pfizer has 10 programs in Phase II, including an ACC inhibitor for non-alcoholic steatohepatitis (NASH), Coagulation Factor IX for hemophilia, Dekavil, an IL-10 agonist, for rheumatoid arthritis, and domagrozumab, a myostatin inhibitor for Duchenne muscular dystrophy (DMD). In a statement, Read said, “our pipeline today, with a range of targeted compounds, biologics and vaccines, is as deep and focused as it has ever been. With several potential near-term opportunities in core therapeutic areas, I believe our pipeline presents an unprecedented opportunity to deliver a life-changing impact on a growing number of patients while creating enhanced value for all of our stakeholders.”

Phase 3Phase 2Financial StatementClinical ResultAcquisition

100 Deals associated with Domagrozumab

External Link

KEGG	Wiki	ATC	Drug Bank
D11047	Domagrozumab	-	DB15083

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscular Dystrophy, Limb-Girdle, Type 2I	Phase 2	United States	Pfizer Inc.	01 Jul 2016
Muscular Dystrophy, Duchenne	Phase 2	United States	Pfizer Inc.	24 Nov 2014
Muscular Dystrophy, Duchenne	Phase 2	Japan	Pfizer Inc.	24 Nov 2014
Muscular Dystrophy, Duchenne	Phase 2	Australia	Pfizer Inc.	24 Nov 2014
Muscular Dystrophy, Duchenne	Phase 2	Bulgaria	Pfizer Inc.	24 Nov 2014
Muscular Dystrophy, Duchenne	Phase 2	Canada	Pfizer Inc.	24 Nov 2014
Muscular Dystrophy, Duchenne	Phase 2	Italy	Pfizer Inc.	24 Nov 2014
Muscular Dystrophy, Duchenne	Phase 2	Poland	Pfizer Inc.	24 Nov 2014
Muscular Dystrophy, Duchenne	Phase 2	United Kingdom	Pfizer Inc.	24 Nov 2014
Muscular Dystrophies	Discovery	Europe	Pfizer Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02841267 (Pubmed) Manual	Phase 1/2	Muscular Dystrophies, Limb-Girdle	19	domagrozumab	myypdomlbf(czuoejptnb) = injuries secondary to falls vozbclcyxs (jhxombcymr )	Negative	01 Aug 2021
NCT02907619 \| NCT02310763 (Pubmed \| Neuromuscul Disord) Manual	Phase 2	Muscular Dystrophy, Duchenne	120	domagrozumab	mtbblfzqeo(eorqgpsfjr): difference = 0.27 (95% CI, -7.4 to 7.9), P-Value = 0.94	Negative	01 Jun 2020
				Placebo
NCT02907619 (CTgov)	Phase 2	Muscular Dystrophy, Duchenne	59	domagrozumab (Sequence 1)	gogpuayokk = vypksuprbv qqxokprcfx (dwzndcycfp, rczkjplmxf - tyibtbpeuu) View more	-	25 Nov 2019
				placebo+domagrozumab (Sequence 2)	gogpuayokk = ecavelifzq qqxokprcfx (dwzndcycfp, mxnpsmrttg - vmsicpllmn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis